GlassScriptPhysician profile
Matthew Richards
NPI 1003255332
$1,981.04
in general payments reported to CMS, 2019-2025
31 companies · $657 in 2025
The $657 reported for 2025 was more than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.04 · 2020: $101 · 2021: $24.74 · 2022: $599 · 2023: $323 · 2024: $263 · 2025: $657.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,051 · Education: $193.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,050.62 |
| Education | $192.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $267.48 | 2025 | 1788 |
| Intuitive Surgical, INC. | $192.71 | 2025 | |
| Merit Medical Systems INC | $183.91 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $162.18 | 2022-2023 | Enhertu |
| Lilly USA, LLC | $159.91 | 2022-2023 | Jaypirca, Verzenio |
| Endologix LLC | $129.93 | 2023 | Afx2 Bifurcated Endograft System |
| Bard Peripheral Vascular, INC. | $79.56 | 2025 | |
| Myriad Genetic Laboratories, INC. | $59.96 | 2023-2025 | Myrisk |
| Boston Scientific Corporation | $57.85 | 2019-2020 | |
| Kci USA, INC. | $56.51 | 2020 | |
| Genmab U.S., INC. | $55.84 | 2023-2024 | Tivdak, Epkinly |
| Merck Sharp & Dohme LLC | $55.43 | 2022-2023 | Lynparza, Keytruda |
| Ge Healthcare | $49.25 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $47.21 | 2023-2024 | Libtayo |
| Daiichi Sankyo INC. | $46.56 | 2024-2025 | Enhertu, Injectafer |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $38.84 | 2024 | Rybrevant, Darzalex |
| Incyte Corporation | $37.05 | 2023-2024 | Jakafi, Monjuvi |
| Beigene USA, INC. | $33.98 | 2024 | Brukinsa |
| Ethicon US, LLC | $33.85 | 2024 | Vistaseal |
| Menarini Silicon Biosystems, INC. | $28.35 | 2025 | |
| Jazz Pharmaceuticals INC. | $25.67 | 2024 | |
| Karyopharm Therapeutics INC. | $25.31 | 2024 | Xpovio |
| Genzyme Corporation | $24.74 | 2021 | |
| Becton, Dickinson and Company | $20.59 | 2022 | |
| Exelixis INC. | $20.18 | 2023 | Cabometyx |
| Servier Pharmaceuticals LLC | $20.09 | 2025 | |
| Astellas Pharma US INC | $16.26 | 2025 | Vyloy |
| Pharmacyclics LLC, An Abbvie Company | $13.62 | 2023 | Imbruvica |
| Coherus Oncology, INC. | $13.49 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.01 | 2022 | |
| Eisai INC. | $11.72 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Richards listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.